# A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT01075464** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 64 (actual)

## Conditions studied

- Solid Cancers

## Interventions

- **DRUG:** MEGF0444A
- **DRUG:** bevacizumab
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT01075464
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01075464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01075464, "A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01075464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*